• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

Research Briefing on 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide (CAS: 1005631-88-8)

In recent years, the compound 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide (CAS: 1005631-88-8) has garnered significant attention in the field of chemical biology and pharmaceutical research. This hydrazide derivative, characterized by its unique pyrazole core and difluoromethyl group, has shown promising potential in various therapeutic applications, particularly in the development of novel antifungal and antibacterial agents. The structural complexity and functional versatility of this compound make it a valuable candidate for further investigation.

Recent studies have focused on elucidating the mechanistic pathways through which 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide exerts its biological effects. One key area of interest is its role as an inhibitor of fungal cytochrome P450 enzymes, which are critical for ergosterol biosynthesis. Disruption of ergosterol production leads to compromised cell membrane integrity in pathogenic fungi, thereby offering a potential therapeutic strategy for treating fungal infections. Preliminary in vitro assays have demonstrated potent activity against Candida albicans and Aspergillus fumigatus, with minimal cytotoxicity to mammalian cells.

In addition to its antifungal properties, this compound has also been explored for its antibacterial potential. Researchers have identified its ability to interfere with bacterial cell wall synthesis by targeting key enzymes involved in peptidoglycan assembly. This dual mechanism of action—targeting both fungal and bacterial pathogens—positions 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide as a promising broad-spectrum antimicrobial agent. However, further in vivo studies are required to validate its efficacy and safety profile in animal models.

The synthesis and optimization of 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide have also been a focal point of recent research. Advances in synthetic chemistry have enabled the production of analogs with improved pharmacokinetic properties, such as enhanced solubility and bioavailability. Structure-activity relationship (SAR) studies have revealed that modifications to the cyclopropyl and difluoromethyl groups can significantly influence the compound's biological activity, providing valuable insights for future drug design efforts.

Despite these promising findings, challenges remain in the clinical translation of this compound. Issues such as metabolic stability, potential drug-drug interactions, and resistance development need to be addressed. Collaborative efforts between academic institutions and pharmaceutical companies are underway to overcome these hurdles and accelerate the development of 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide-based therapeutics.

In conclusion, 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide represents a compelling area of research in the chemical biology and pharmaceutical sectors. Its unique structural features and multifaceted biological activities underscore its potential as a lead compound for the development of next-generation antimicrobial agents. Continued research and innovation will be essential to fully realize its therapeutic promise.

• 1001500-11-3(2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetic acid)
• 1004644-67-0(2-4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetohydrazide)
• 1002033-75-1(ethyl 2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetate)
• 1001518-92-8(2-[4-bromo-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid)
• 1004644-16-9(2-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide)
• 299405-22-4(2-(4-Bromo-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetamide)
• 1005644-36-9(<br>2-(4-Bromo-5-cyclopropyl-3-difluoromethyl-pyrazol-1-yl)-1-pyrrolidin-1-yl-e thanone)
• 1001518-83-7(2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylacetohydrazide)
• 1001518-93-9(2-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetohydrazide)
• 1005692-61-4(<br>2-(4-Bromo-5-cyclopropyl-3-difluoromethyl-pyrazol-1-yl)-N,N-diethyl-acetami de)